Stock Scorer

Aktis Oncology, Inc. (AKTS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 1.5M 3M 4.5M Q1 '25: 1.4M Q2 '25: 1.6M Q1 '26: 3.2M Q2 '26: 3.4M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating Income Quarterly

-30M -20M -10M 0 10M 20M 30M Q1 '25: -18.1M Q2 '25: -21M Q1 '26: -22.7M Q2 '26: -28.9M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Net Income Quarterly

-27M -18M -9M 0 9M 18M 27M Q1 '25: -15M Q2 '25: -18.1M Q1 '26: -18.3M Q2 '26: -24.1M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-27M -18M -9M 0 9M 18M 27M Q1 '25: -17.5M Q2 '25: -16.2M Q1 '26: -24.2M Q2 '26: -20.6M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-27M -18M -9M 0 9M 18M 27M Q1 '25: -19.4M Q2 '25: -17.7M Q1 '26: -26.1M Q2 '26: -21.8M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '25: 805.8K Q2 '25: 807.3K Q1 '26: 48.6M Q2 '26: 55.3M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

Not drawn for AKTS: Gross Profit, Cost of Revenue, EPS. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.